Esperion Therapeutics (NASDAQ:ESPR) shares gained 7% premarket on Monday after the company touted clinical benefits of NEXLETOL (bempedoic acid) tablets in diverse populations, including women, Hispanic/Latinx, and patients with obesity.
Bempedoic acid is the only FDA-approved non-statin LDL lowering therapy to demonstrate reductions in major adverse cardiovascular events (MACE) in both primary prevention and secondary prevention patient populations.
Results from the CLEAR Cardiovascular Outcomes Trial showed that patients with obesity who took NEXLETOL were 23% less likely to experience MACE-4 (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization), compared to placebo.
Hispanic/Latinx patients represented almost 17% of those enrolled in the CLEAR Outcomes trial. This subgroup analysis showed a similar 21% lowering of LDL-C with bempedoic acid, compared to placebo in Hispanic/Latinx and non-Hispanic/Latinx alike.
Furthermore, the risk of MACE-4 was similarly reduced for women treated with bempedoic acid compared to placebo.
CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL (bempedoic acid) tablet and NEXLIZET (bempedoic acid and ezetimibe) tablet.
